Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes Mellitus
NCT02367131 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 419
Last updated 2024-03-08
Summary
Study to investigate the safety and efficacy of daily use of JARDIANCE® Tablets in Japanese elderly patients with type 2 diabetes mellitus.
Conditions
- Diabetes Mellitus, Type 2
Interventions
- DRUG
-
JARDIANCE®
Sponsors & Collaborators
- collaborator INDUSTRY
- lead INDUSTRY
Principal Investigators
-
Boehringer Ingelheim · Boehringer Ingelheim
Eligibility
- Min Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-02-24
- Primary Completion
- 2016-09-27
- Completion
- 2016-09-27
Countries
- Japan
More Related Trials
-
Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus
NCT02589639 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of LY3209590 in Japanese Participants With Type 2 Diabetes
NCT03603704 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes
NCT03315780 ·Status: COMPLETED ·Phase: PHASE4
-
Forxiga Tablets Specific Clinical Experience Investigation for Elderly
NCT02200627 ·Status: COMPLETED
-
Safety and Tolerability Study of MEDI0382 in Japanese Preobese or Obese Subjects With Type 2 Diabetes
NCT03645421 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Test How Well Empagliflozin Works in Japanese People With Type 2 Diabetes Who Are Older Than 65 Years
NCT04531462 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes
NCT02750410 ·Status: COMPLETED ·Phase: PHASE4
-
Clinical Assessment of GSK716155 for Type 2 Diabetes Mellitus
NCT00530309 ·Status: COMPLETED ·Phase: PHASE1
-
To Study Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 in Japanese Type 2 Diabetes Mellitus (T2DM) Patients
NCT00916604 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Investigate Multiple Ascending Doses of AZD5004 in Healthy Japanese Participants and Participants With Type 2 Diabetes Mellitus
NCT06703658 ·Status: COMPLETED ·Phase: PHASE1
-
Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus
NCT01650259 ·Status: COMPLETED
-
Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus
NCT01294436 ·Status: COMPLETED ·Phase: PHASE3
-
MK-0941 Multiple Dose Study in Japanese Patients With Type 2 Diabetes (MK-0941-011).
NCT00754130 ·Status: COMPLETED ·Phase: PHASE1
-
Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus
NCT01368081 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes
NCT03322631 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS as Tablet in Patients With Type 2 Diabetes
NCT02183415 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of LY3549492 in Japanese Participants With Type 2 Diabetes Mellitus (T2D) and Healthy Japanese Participants
NCT06869018 ·Status: COMPLETED ·Phase: PHASE1
-
Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus
NCT01193218 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes Mellitus
NCT01294423 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus
NCT05086445 ·Status: COMPLETED ·Phase: PHASE1
-
Phase II Dose-Finding Study of SK-0403 With Type 2 Diabetes Mellitus
NCT00532506 ·Status: COMPLETED ·Phase: PHASE2
-
Japan Dose Regimen Study of AZD1656 in Japanese Type 2 Diabetes Mellitus Patients
NCT01152385 ·Status: COMPLETED ·Phase: PHASE2
-
A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)
NCT01733758 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control
NCT00621140 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 1 Study In Japanese Subjects With Type 2 Diabetes Mellitus As Monotherapy
NCT02292433 ·Status: COMPLETED ·Phase: PHASE1